Showing 15,041 - 15,060 results of 22,917 for search '(( 50 ((mean decrease) OR (we decrease)) ) OR ( 59 ((nn decrease) OR (a decrease)) ))', query time: 1.10s Refine Results
  1. 15041
  2. 15042

    DataSheet1_Novel indazolylchromones: synthesis, fungicidal evaluation, molecular docking and aquatic toxicity prediction.docx by Riya Kundu (18801799)

    Published 2024
    “…The acute toxicity predictions the of synthesized compounds for fish (LC<sub>50</sub>,96 Hr), daphnid (LC<sub>50</sub>, 48 Hr) and green algae (EC<sub>50</sub>, 96Hr) and the chronic toxicity predictions (ChV) were assessed using Ecological Structure Activity Relationship (ECOSAR) model. …”
  3. 15043

    Suf/Spastizin controls cortical granule maturation. by Palsamy Kanagaraj (589557)

    Published 2014
    “…Note the decreased elevation of the chorion in mutants. Scale bar: 100 µm. …”
  4. 15044

    Metabolic Erosion Primarily Through Mutation Accumulation, and Not Tradeoffs, Drives Limited Evolution of Substrate Specificity in <i>Escherichia coli</i> by Nicholas Leiby (424634)

    Published 2014
    “…<div><p>Evolutionary adaptation to a constant environment is often accompanied by specialization and a reduction of fitness in other environments. We assayed the ability of the Lenski <i>Escherichia coli</i> populations to grow on a range of carbon sources after 50,000 generations of adaptation on glucose. …”
  5. 15045
  6. 15046
  7. 15047

    Included studies basic characteristics. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  8. 15048

    Forest plot for FVC. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  9. 15049

    All data extracted. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  10. 15050

    Forest plot for TNF- by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  11. 15051
  12. 15052

    Evaluation of HLB epidemic progress in southern California vs survey data and the impact of quarantine radius to epidemic outcome. by Viet-Anh Nguyen (137745)

    Published 2023
    “…<p>(A) Temporal progression of the prevalence of three infection categories (Exposed, Infectious, and Detected) in comparison with the training and testing data. We show means of 1000 simulation realizations as solid lines, and 50%, 75%, 95% credible intervals as shades of decreasing intensities. …”
  13. 15053
  14. 15054

    Reduced nanodomain segregation, signaling, and internalization of the palmitoylation-deficient GLP-1R C438A mutant. by Teresa Buenaventura (4768041)

    Published 2019
    “…All data are shown as mean ± SEM, with individual replicates indicated where relevant. …”
  15. 15055

    Validation of model predictions of growth during infusion of hypertrophic agonists with and without receptor blockers. by Johane H. Bracamonte (12883844)

    Published 2025
    “…<p>a) Boxplot shows the mean, 50% confidence interval, and 90% confidence interval for predicted normalized growth in 1000 MC simulations of ISO infusion with the calibrated network. …”
  16. 15056
  17. 15057

    CgA silencing, processing enzyme inhibition and functional analysis of CgA peptides in SI-NEN cell lines. by Francesco Giovinazzo (487256)

    Published 2013
    “…Inhibition of the CgA processing enzyme prohormone convertase using Decanoyl-Arg-Val-Lys-Arg-CMK also decreased proliferation of H-STS cells (25 µM [<i>data not shown</i>] and 50 µM, <b>4D</b>, *<i>p</i><0.05). …”
  18. 15058

    Image 1_Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly.tif by Chaitanya Gandhi (20644727)

    Published 2025
    “…</p>Results<p>Ten patients (8 males) with mean age of 50.7 years participated in the study. …”
  19. 15059

    Network Signatures of Survival in Glioblastoma Multiforme by Vishal N. Patel (242677)

    Published 2013
    “…In particular, the long-term survivor subtype was characterized by increased protein expression of DNM1 and MAPK1 and decreased expression of HSPA9, PSMD3, and CANX. Overall, we demonstrate that the combinatorial analysis of gene expression data constrained by PPIs outlines an approach for the discovery of robust and translatable molecular signatures in GBM.…”
  20. 15060

    Primary and secondary outcomes. by Axel Cosmus Pyndt Diederichsen (3134508)

    Published 2024
    “…<div><p>Background</p><p>The Danish cardiovascular screening (DANCAVAS) trial, a nationwide trial designed to investigate the impact of cardiovascular screening in men, did not decrease all-cause mortality, an outcome decided by the investigators. …”